Welcome to the Microbiome Drug Database, a live tool, updated on a regular basis, to depict as accurately as possible, the current microbiome pharma landscape. It is the most comprehensive global database of microbiome biotechs developing pharmaceuticals, consisting of over 220 companies and 700 active research programs. See the full definitions and exclusion criteria of the analysis here.
Annual Subscription: €2950
(exc. VAT) per organisation.
Should you have any questions or would like to schedule a demo, please contact us here and a member of our team will be in touch.
Who should Subscribe to the Microbiome Drug Database and Why?
Therapeutic Application
Search by each research programme’s Therapeutic Application, including Oncology, Gut-Brain Axis, Immune-Mediated Diseases, Dermatology, Metabolic Diseases and Infectious Diseases
Therapeutic Approach
Browse by the Therapeutic Approach employed by each research programme, including: Faecal Transplant, Defined Consortium, Single Strain, Postbiotics, Small molecules, GMO microorganisms, Bacteriophages and Microbiome-Based Diagnostics.
Development Stage
Filter by the Stage in which is research program currently is.
A useful tool to search preclinical vs clinical-stage companies.
Geography
Find companies by Geography.
Whereas over the majority of microbiome biotechs are based in the USA, Canada or Europe, a growing number of them are being founded in other geographies like China, South Korea and Israel.